Results 201 to 210 of about 289,022 (294)

Self‐Accelerating Bimetallic Peroxide Nanozymes for Cascade‐Amplified Pyroptosis‐Immunotherapy

Advanced Science, EarlyView.
Acidic tumor microenvironment‐responsive CuZnONPs enable triple‐combination therapy via self‐supplying H2O2, cascade nanozyme activities for ROS burst, and Zn2+‐activated pyroptosis, synergizing catalytic therapy with immunotherapy to convert cold tumors into hot ones.
Xuanyi Lu, Liang Li, Siyu Pan, Yuehan Jian, Yuhan Chen, Wenjie Yang, Guang Song, Xueyang Fang, Ping'an Ma, Lijun Jiang   +9 more
wiley   +1 more source

High PD-1 expression in pre-treatment peripheral lymphocytes associated with poor immune checkpoint inhibitor response in patients with recurrent or metastatic head and neck squamous cell carcinoma. [PDF]

Cancer Immunol Immunother
Li SH, Huang WT.
europepmc   +1 more source

Mature Tertiary Lymphoid Structures Indicate Good Chemotherapy Response and Prognosis in Advanced Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
In advanced colorectal cancer, tumors with mature tertiary lymphoid structures (TLS) exhibited abundant infiltration of CD3‐ and CD8‐positive lymphocytes in both primary and metastatic sites, indicating an activated immune response. The presence of mature TLS was also associated with favorable chemotherapy sensitivity and improved prognosis.
Nobuhiro Hosoi, Chika Komine, Gendensuren Dorjkhorloo, Takuya Shiraishi, Takuhisa Okada, Akihiko Sano, Makoto Sakai, Takehiko Yokobori, Ken Shirabe, Hiroshi Saeki   +9 more
wiley   +1 more source

An Immunomodulating Peptide With Potential to Counteract Endometriosis. [PDF]

Aust N Z J Obstet Gynaecol
Agrez M.
europepmc   +1 more source

Association of HAMP Expression and CD8+ T‐Cell Infiltration With Atezolizumab–Bevacizumab Response in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura, Yuki Murakami, Yusuke Oshima, Takashi Masuda, Wataru Miyoshino, Hiroomi Takayama, Yoko Kawano, Teijiro Hirashita, Yuichi Endo, Masafumi Inomata   +9 more
wiley   +1 more source

Flow cytometric evaluation of monoclonal antibodies for cross-reactivity with feline leukocytes. [PDF]

Front Vet Sci
Krüger H, Moritz A, Roshani B, Neumann S.   +3 more
europepmc   +1 more source

Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown.
Takayoshi Sasaki, Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Yuzo Harada, Soichiro Ishihara   +9 more
wiley   +1 more source

Aggressive GATA-3 Positive Primary Cutaneous Peripheral T-Cell Lymphoma - Not Otherwise Specified Masquerading as CD-4 Positive Small/Medium T-Cell Lymphoproliferative Disorder: Where is the Line of Delineation?

Indian J Dermatol
Kapetanovic I, Bosic M, Zivanovic D.
europepmc   +1 more source

Unique pattern of endometrial invasion in gastric-type adenocarcinoma of the uterine cervix: a report of two cases. [PDF]

Int Cancer Conf J
Kamijo K, Miyamoto T, Ando H, Kobara H, Satoh Y, Kobayashi Y, Shiozawa T.   +6 more
europepmc   +1 more source

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes

American Journal of Hematology, EarlyView.
ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth.
Arushi Khurana, Hikaru Hayashi, Bethany Thach, Zhi Zhang Yang, Brianna J. Negaard, James R. Cerhan, Anne J. Novak, Brian K. Link, Thomas M. Habermann, Andrew L. Feldman, Sameer A. Parikh, Susan L. Slager, Stephen M. Ansell, Matthew J. Maurer, Denise L. Faustman   +14 more
wiley   +1 more source